Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

2.260 UNCHANGED
Streaming Delayed Price Updated: 1:31 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,037
Open 2.300
Bid (Size) 2.260 (1)
Ask (Size) 2.280 (1)
Prev. Close 2.260
Today's Range 2.220 - 2.390
52wk Range 1.880 - 6.140
Shares Outstanding 43,738,865
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
 
Via Benzinga
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire

Performance

YTD
-8.50%
-8.50%
1 Month
-13.41%
-13.41%
3 Month
+9.18%
+9.18%
6 Month
-33.14%
-33.14%
1 Year
-45.15%
-45.15%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
Via Benzinga
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why Pinterest Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
Via Benzinga
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Via Benzinga
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
From CEL-SCI Corporation
Via Business Wire
TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Shares Replays of 2022 LD Micro Invitational Company Presentations
Via Investor Brand Network
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
CEL-SCI Corporation to Present at LD Micro Invitational
From CEL-SCI Corporation
Via Business Wire
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Publication of ASCO 2022 Abstracts
From CEL-SCI Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.